The mechanisms of vasorelaxation elicited by N -hydroxy-Larginine (L-NOHA) and other compounds bearing a CϭNOH function and the structural determinants governing this effect were investigated in rat aorta. L-NOHA, formamidoxime, five aromatic monosubstituted amidoximes, and one aromatic monosubstituted ketoxime elicited relaxation in endothelium-denuded rings. N-Hydroxyguanidine and substituted N-hydroxyguanidines were markedly less active. Relaxations induced by L-NOHA and by the most active studied compound, 4-chlorobenzamidoxime (ClBZA), were unmodified by the presence of endothelium. In endothelium-denuded rings, they were blunted by the NO scavenger 2-phenyl-4,4,5,5-tetramethyl-imidazoline-1-oxyl-3-oxide (300 M) and by the inhibitor of guanylylcyclase activation 1H[1,2,4,]oxadiazolo[4,3-a]quinoxalin-1-one (1 M). In addition, L-NOHA-and ClBZA both caused cGMP accumulation. L-Arginine, but not D-arginine (1 mM), antagonized the effect of L-NOHA but not ClBZA. Both L-NOHA-and ClBZA-induced relaxations were inhibited by the NAD(P)H-dependent enzymes inhibitor diphenyliodonium (30 M) and the NAD(P)H-dependent reductases inhibitor 7-ethoxyresorufin (10 M), but they were unmodified by the cytochrome P450 (P450) inhibitor proadifen (10 M) and by the NO synthase inhibitor N -nitro-L-arginine methyl ester (L-NAME, 300 M). These results show that L-NOHA and other compounds with a CϭNOH function can cause endothelium-independent relaxation in the rat aorta. They suggest that activation of guanylyl cyclase and NO formation is implicated in relaxation and that a 7-ethoxyresorufin-sensitive NAD(P)H-dependent pathway is involved. On one hand, L-NOHA and amidoximes may be useful tools for characterizing this pathway in blood vessels and, on the other, may offer a novel approach for treating vascular diseases with impaired endothelial NO activity.